Renal transplantation requires lifelong pharmacological suppression of the recipient's immune response against the donor allograft. The fundamental challenge is achieving sufficient immunosuppression to prevent rejection while avoiding the cumulative toxicities of the immunosuppressive agents themselves and the consequences of over-immunosuppression, principally opportunistic infection and malignancy. Modern transplant immunosuppression employs a three-phase strategy: intense induction therapy in the immediate perioperative period, followed by triple-drug maintenance immunosuppression for life, with additional treatment protocols activated when rejection occurs. Each phase uses agents targeting distinct steps in T-cell activation, proliferation, and effector function, with the combination achieving synergistic suppression while limiting individual drug toxicity through dose reduction.
Induction immunosuppression is administered in the first days to weeks after transplantation, the period of highest alloimmune risk when the recipient's immune system encounters donor antigens for the first time and naive alloreactive T cells are activated in large numbers. Induction agents are highly potent and are not used long-term due to their toxicity profiles. Basiliximab, a chimeric monoclonal antibody targeting the interleukin-2 receptor alpha chain (IL-2Rα, CD25), blocks interleukin-2 (IL-2)-driven T-cell proliferation with low direct toxicity. Antithymocyte globulin (ATG) is a polyclonal preparation of anti-human thymocyte antibodies derived from immunized rabbits or horses; it depletes circulating T cells profoundly and is used in higher-risk recipients or as an alternative to basiliximab. The choice between basiliximab and ATG is guided by immunological risk: standard-risk recipients typically receive basiliximab; high-risk recipients (highly sensitized patients, repeat transplants, living donor mismatched grafts) receive ATG for deeper initial immunosuppression.112
Maintenance immunosuppression is the lifelong triple-drug regimen that prevents chronic rejection. The standard combination is a calcineurin inhibitor (CNI) plus an antiproliferative agent plus a corticosteroid. Tacrolimus is the preferred CNI in most contemporary protocols given its superior efficacy in preventing acute rejection compared with cyclosporine. Mycophenolate mofetil (MMF) has replaced azathioprine as the preferred antiproliferative agent in most centers due to its greater selectivity for lymphocyte purine synthesis. Corticosteroids are tapered over the first weeks to months to the lowest effective dose, and steroid-free protocols are increasingly used in low-immunological-risk patients. The rationale for triple-drug therapy is synergistic immunosuppression at individually lower doses, reducing the cumulative toxicity burden of each agent.12
Rejection treatment is initiated when clinical or biopsy-confirmed rejection occurs. The treatment protocol depends on the rejection type. T-cell mediated rejection (TCMR) is treated with pulse corticosteroids (methylprednisolone 500 mg intravenously daily for three days); steroid-resistant TCMR is treated with ATG. Antibody-mediated rejection (AMR), driven by donor-specific antibodies (DSAs) against donor human leukocyte antigens (HLAs), is substantially more difficult to treat and carries a worse prognosis than TCMR; it is addressed with plasmapheresis to remove circulating DSAs, intravenous immunoglobulin (IVIG) to modulate B-cell and antibody-mediated effector mechanisms, and rituximab (anti-CD20 monoclonal antibody) to deplete B cells and reduce de novo donor-specific antibody (DSA) production.1
Calcineurin inhibitors (CNIs) are the pharmacological cornerstone of transplant maintenance immunosuppression. Despite binding to different intracellular proteins, tacrolimus and cyclosporine converge on the same downstream target. Tacrolimus (also called FK506) binds the cytoplasmic immunophilin FK506-binding protein 12 (FKBP12), and the tacrolimus-FKBP12 complex potently inhibits calcineurin, a calcium-calmodulin-dependent serine-threonine phosphatase. Cyclosporine binds cyclophilin, and the cyclosporine-cyclophilin complex inhibits the same calcineurin enzyme. Calcineurin normally dephosphorylates the transcription factor nuclear factor of activated T cells (NFAT), allowing NFAT to translocate to the nucleus and activate interleukin-2 (IL-2) gene transcription. Calcineurin inhibitor (CNI)-mediated calcineurin inhibition prevents NFAT dephosphorylation, blocking IL-2 production and the autocrine T-cell proliferative signal that it drives. The result is selective impairment of T-cell activation without the broad myelosuppression of cytotoxic agents.23
Both tacrolimus and cyclosporine are substrates of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) efflux transporter, making them targets of a massive drug interaction network. CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, diltiazem, verapamil, grapefruit juice, ritonavir-boosted antiretrovirals) dramatically increase CNI plasma levels and risk toxicity. CYP3A4 inducers (rifampin, rifabutin, phenytoin, carbamazepine, St. John's wort) reduce CNI levels and risk rejection. Both agents have narrow therapeutic indices, and trough level monitoring is mandatory throughout the post-transplant course: tacrolimus target trough is 8–12 ng/mL in the early post-transplant period, tapering to 5–8 ng/mL once the graft is stable; cyclosporine target varies by center and assay, either a pre-dose trough level sampled before the morning dose, or a level drawn two hours after the morning dose. Bioavailability of both agents varies substantially with food, formulation, and gastrointestinal function, making any significant gastrointestinal illness a trigger for urgent CNI level monitoring.23
CNI nephrotoxicity is the most clinically important adverse effect. Acute CNI nephrotoxicity results from afferent arteriolar vasoconstriction mediated by increased production of thromboxane A2 (TXA2) and endothelin, which reduce renal blood flow and glomerular filtration rate (GFR) in the allograft. This is dose-related and reversible with dose reduction; it must be distinguished from acute rejection as both present with rising creatinine, and only renal biopsy reliably differentiates them. Chronic CNI nephrotoxicity arises from long-term stimulation of transforming growth factor beta (TGF-β) signaling in renal tubular and interstitial cells, driving progressive striped tubulointerstitial fibrosis that is largely irreversible and is a leading cause of late allograft dysfunction. Strategies to minimize chronic CNI nephrotoxicity include minimization of CNI dose over time, CNI-sparing protocols using mTOR inhibitors, and consideration of CNI-free regimens in selected patients with established fibrosis on biopsy.23
Tacrolimus and cyclosporine have divergent adverse effect profiles that influence agent selection. Cyclosporine produces gingival hyperplasia and hirsutism through as-yet incompletely characterized mechanisms; these adverse effects are not seen with tacrolimus. Tacrolimus causes alopecia and has substantially higher rates of post-transplant diabetes mellitus (PTDM) than cyclosporine, attributed to tacrolimus-mediated inhibition of insulin secretion from pancreatic beta cells through calcineurin-NFAT pathway disruption in the pancreas. Both agents cause hypertension and hyperlipidemia. Tacrolimus is associated with greater neurotoxicity than cyclosporine, including tremor, headache, peripheral neuropathy, and rarely posterior reversible encephalopathy syndrome (PRES). These comparative profiles explain why tacrolimus is preferred in most protocols despite its higher PTDM incidence, as its superior rejection prevention and absence of gingival/cosmetic adverse effects are clinically prioritized.23
Both acute CNI toxicity and acute allograft rejection present with rising serum creatinine. Supratherapeutic CNI levels support toxicity; subtherapeutic levels support rejection. Clinical features overlap substantially. Biopsy is required for definitive diagnosis: CNI toxicity shows vacuolization of tubular cells and afferent arteriolar hyalinosis without significant lymphocytic infiltration; rejection shows lymphocytic tubulitis and intimal arteritis (TCMR) or peritubular capillary C4d deposition and microvascular injury (AMR). Never treat empirically for rejection without ruling out CNI toxicity and checking levels.
Mycophenolate mofetil (MMF) is a prodrug that is rapidly hydrolyzed to mycophenolic acid (MPA), the active compound, by intestinal and hepatic esterases after oral absorption. MPA is an uncompetitive inhibitor of inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in the de novo purine synthesis pathway. T and B lymphocytes are uniquely dependent on de novo purine synthesis for proliferation because, unlike most other cell types, they largely lack salvage pathway capacity to recycle purine bases. IMPDH inhibition therefore selectively impairs lymphocyte proliferation while largely sparing other rapidly dividing cells that can use the purine salvage pathway. MPA undergoes extensive enterohepatic recirculation after glucuronidation in the liver: the MPA glucuronide (MPAG) is excreted in bile, deconjugated by intestinal bacteria to regenerate MPA, and reabsorbed, producing a secondary plasma peak at 6–12 hours after dosing that contributes meaningfully to total drug exposure. This enterohepatic recirculation is disrupted by antibiotics that eliminate intestinal flora, potentially reducing MMF efficacy during antibiotic courses, and by cholestyramine, which traps MPAG in the gut and reduces systemic MPA levels. Antacids (aluminum and magnesium hydroxide) impair MMF absorption when co-administered.4
The principal adverse effects of MMF are gastrointestinal: nausea, vomiting, diarrhea, and abdominal cramping, which are dose-limiting in 20–30% of patients. Substitution with mycophenolate sodium (enteric-coated formulation) may reduce upper gastrointestinal adverse effects through delayed gastric release but does not meaningfully reduce lower gastrointestinal (GI) effects, as much of the GI toxicity is mediated locally by MPA at the intestinal epithelium. Bone marrow suppression (leukopenia, anemia, thrombocytopenia) occurs less commonly but requires monitoring. MMF carries a US FDA Risk Evaluation and Mitigation Strategy (REMS) program due to its teratogenicity: it causes characteristic embryopathy including external ear abnormalities, cleft lip/palate, and cardiac defects. Women of reproductive age must use two forms of contraception while on MMF and for six weeks after discontinuation, and pregnancy testing is required before initiation.4
Azathioprine is a thiopurine prodrug that is converted to 6-mercaptopurine (6-MP) and further metabolized to active thioguanine nucleotides that incorporate into replicating deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), causing strand breaks and inhibiting purine synthesis through multiple steps. Unlike MMF, azathioprine lacks lymphocyte selectivity and suppresses all rapidly dividing cells, including bone marrow progenitors. Thiopurine methyltransferase (TPMT) is the principal enzyme that inactivates 6-MP through S-methylation; patients with low TPMT activity (approximately 1 in 300 individuals are TPMT-deficient due to homozygous loss-of-function variants in the TPMT gene) accumulate thioguanine nucleotides to toxic levels, causing life-threatening myelosuppression at standard doses. TPMT genotyping or phenotyping before azathioprine initiation is recommended to identify at-risk patients. A clinically critical drug interaction exists between azathioprine and allopurinol (or febuxostat): xanthine oxidase is the primary enzyme responsible for azathioprine catabolism, and xanthine oxidase inhibition by allopurinol blocks azathioprine inactivation, dramatically increasing thioguanine nucleotide accumulation and the risk of profound myelosuppression. If the combination cannot be avoided, azathioprine dose must be reduced by approximately 75%. MMF does not share this interaction and is the preferred antiproliferative in patients requiring allopurinol.45
Allopurinol inhibits xanthine oxidase, which is required to catabolize azathioprine. Co-administration leads to massive accumulation of active thioguanine nucleotides and life-threatening myelosuppression — pancytopenia, agranulocytosis, and fatal infections have been reported. This is one of the highest-severity drug interactions in transplant medicine. If allopurinol must be used (e.g., for gout), the azathioprine dose must be reduced by 75%, or preferably, azathioprine should be replaced with MMF, which does not interact with xanthine oxidase inhibitors.
Mechanistic target of rapamycin (mTOR) inhibitors sirolimus and everolimus bind the immunophilin FKBP12 (FK506-binding protein 12) just as tacrolimus does, but the sirolimus-FKBP12 complex does not inhibit calcineurin. Instead, it binds and inhibits mTOR complex 1 (mTORC1), a serine-threonine kinase that integrates growth factor, nutrient, and energy signals to coordinate cell growth, protein synthesis, and cell cycle progression. mTORC1 inhibition arrests T-cell proliferation at the G1 (first gap) to S (synthesis) phase transition by preventing the upregulation of cell cycle machinery that interleukin-2 (IL-2) receptor signaling drives. Because mTOR inhibitors act downstream of IL-2 receptor signaling rather than blocking IL-2 production like calcineurin inhibitors (CNIs), they are complementary rather than redundant with CNIs and are used in combination or as calcineurin inhibitor-sparing alternatives.6
The principal clinical role of mTOR inhibitors in renal transplantation is calcineurin inhibitor (CNI) minimization or elimination in patients with established or at-risk-for CNI nephrotoxicity. Because mTOR inhibitors themselves are not nephrotoxic through the CNI mechanism, protocols that substitute or reduce the CNI with mTOR inhibitors can attenuate the progressive interstitial fibrosis of chronic CNI toxicity. Sirolimus and everolimus differ primarily in their pharmacokinetics: everolimus has a shorter half-life (approximately 28 hours vs. 62 hours for sirolimus) and is more commonly used in combination with reduced-dose tacrolimus in contemporary CNI-minimization protocols. Both agents require trough level monitoring, with target ranges of 4–12 ng/mL depending on the protocol and concomitant immunosuppression.6
The adverse effect profile of mTOR inhibitors limits their use particularly in the early post-transplant period. Wound healing impairment is a class effect: mTOR signaling is required for the proliferation of fibroblasts and endothelial cells needed for wound repair, and mTOR inhibition impairs anastomotic healing, increases wound dehiscence risk, and is associated with lymphocele formation around the graft. mTOR inhibitors are therefore generally avoided for at least four to six weeks after transplant surgery and are not used perioperatively. Additional adverse effects include hyperlipidemia (often severe, requiring statin therapy), mouth ulcers (aphthous-type stomatitis), non-infectious pneumonitis (which can present as progressive dyspnea and ground-glass opacities on computed tomography, requiring drug discontinuation), and proteinuria through podocyte mTOR inhibition. mTOR inhibitors also have documented antiproliferative effects on cancer cells, which is clinically exploited in recipients with post-transplant malignancy or at high malignancy risk.6
Corticosteroids contribute to transplant immunosuppression through broad suppression of nuclear factor kappa B (NF-κB), a transcription factor that drives the expression of multiple pro-inflammatory cytokines including interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and interferon gamma (IFN-γ). Glucocorticoids bind the glucocorticoid receptor (GR) in the cytoplasm, causing nuclear translocation and direct interaction with NF-κB subunits that prevents their deoxyribonucleic acid (DNA) binding and cytokine gene activation. This broad anti-inflammatory mechanism is distinct from the T-cell-specific actions of CNIs and antiproliferatives, making corticosteroids a synergistic component of the triple-drug maintenance regimen. In the immediate post-transplant period, high-dose methylprednisolone (500–1000 mg intravenously at transplant) is administered as part of induction; thereafter, oral prednisone is tapered over weeks to months to a maintenance dose of 5–10 mg daily in most protocols.7
The cumulative metabolic and musculoskeletal toxicity of long-term corticosteroid use drives ongoing efforts at steroid minimization and steroid-free protocols. Post-transplant diabetes mellitus is caused by corticosteroid-mediated insulin resistance and impaired beta-cell secretory response; this risk is additive with tacrolimus-mediated beta-cell calcineurin inhibition. Osteoporosis results from corticosteroid-driven suppression of osteoblast differentiation and function, increased osteoclast activity, reduced intestinal calcium absorption, and impaired renal calcium conservation; all transplant recipients should receive calcium and vitamin D supplementation and be monitored by dual-energy X-ray absorptiometry (DEXA). Avascular necrosis of the femoral head and other large joints is an underrecognized complication of high-dose corticosteroid exposure in the early transplant period; it presents months to years later with progressive hip or shoulder pain and is diagnosed by magnetic resonance imaging (MRI). Adrenal suppression from prolonged exogenous corticosteroid use requires stress-dose corticosteroid coverage for surgical procedures and acute illness in transplant recipients on maintenance steroids. Steroid-free maintenance protocols, now increasingly used in low-risk recipients, reduce these metabolic burdens but require close monitoring for subclinical rejection.7
Basiliximab is a chimeric (human-mouse) monoclonal antibody directed against the interleukin-2 receptor alpha chain (IL-2Rα, CD25), which is expressed on activated T cells. By occupying CD25 and blocking interleukin-2 (IL-2) binding, basiliximab prevents the high-affinity IL-2 receptor signaling that drives clonal T-cell expansion in response to alloantigens. Basiliximab does not deplete T cells; it prevents their IL-2-driven proliferation without causing lymphopenia or the cytokine release syndrome that T-cell-depleting agents produce. The standard dosing is two doses of 20 mg intravenously: one within two hours before transplant and one on post-operative day four. Its long half-life (approximately seven days) provides CD25 saturation throughout the critical early post-transplant window. Basiliximab is generally well tolerated, with no significant infusion reactions in most patients and no increase in opportunistic infection risk above background immunosuppression.18
Antithymocyte globulin (ATG) is a polyclonal preparation produced by immunizing rabbits (rabbit ATG, rATG, brand name Thymoglobulin) or horses (equine ATG, eATG, brand name ATGAM) with human thymocytes and purifying the resulting antibodies. The resulting polyclonal antibody pool recognizes a broad panel of T-cell surface cluster of differentiation (CD) antigens, causing complement-mediated and cell-mediated T-cell depletion through lysis and opsonization. ATG reduces circulating T cells to very low levels within hours of infusion and maintains profound lymphopenia throughout the induction course (typically 1.5 mg/kg/day for 3–7 days in induction; 1.5 mg/kg/day for 10–14 days in steroid-resistant rejection treatment). Infusion reactions (fever, chills, hypotension, serum sickness) are common and require premedication with corticosteroids, acetaminophen, and antihistamines before each dose. Lymphocyte count monitoring guides dosing and discontinuation, with target total lymphocyte counts typically below 0.05×10⁵/L or T-cell (CD3+) counts below 25 cells/mm³ during treatment. The profound immunosuppression of ATG increases the risk of cytomegalovirus (CMV) reactivation and disease, necessitating universal antiviral prophylaxis with ganciclovir or valganciclovir for several months after ATG exposure.18
Standard immunological risk (first transplant, low panel reactive antibody, no prior sensitization): basiliximab preferred — adequate efficacy with lower toxicity and infection risk. High immunological risk (sensitized patients with panel reactive antibody above 30%, repeat transplant, donor-specific antibody detected, extended-criteria donor organ): ATG preferred for deeper initial T-cell depletion. ATG is also the treatment for steroid-resistant TCMR regardless of what was used for induction. The two agents are never used together in induction — that would constitute double T-cell targeting with additive infection risk and no established additional benefit.
Acute rejection following renal transplantation is classified by the Banff histopathological criteria into T-cell mediated rejection (TCMR) and antibody-mediated rejection (AMR), with distinct mechanisms, diagnostic signatures, and treatment approaches. Clinical presentation of acute rejection includes rising serum creatinine, decreased urine output, graft tenderness, and in severe cases, systemic inflammatory signs. These features are nonspecific, and the differential diagnosis includes calcineurin inhibitor (CNI) toxicity, acute kidney injury from hypovolemia or obstruction, infection, and drug toxicity. Allograft biopsy with histopathology and immunofluorescence (for C4d deposition) combined with donor-specific antibody (DSA) testing is required for definitive rejection classification and treatment selection.9
T-cell mediated rejection (TCMR) is characterized histologically by lymphocytic tubulitis (mononuclear cell infiltration of tubular epithelium), interstitial inflammation, and in severe cases, endotheliitis (lymphocytic intimal arteritis). TCMR is graded IA/IB (tubulointerstitial) and IIA/IIB/III (vascular) by Banff criteria, with higher grades indicating more severe rejection. First-line treatment is pulse methylprednisolone 500 mg intravenously daily for three consecutive days; approximately 70–80% of acute TCMR episodes respond to pulse steroids with reversal of the creatinine rise within one to two weeks. Steroid-resistant TCMR (creatinine not returning toward baseline within five to seven days of pulse steroids) is treated with antithymocyte globulin (ATG) at 1.5 mg/kg/day for 10–14 days, which depletes the alloreactive T-cell population driving rejection. Optimization of maintenance immunosuppression (ensuring CNI levels are therapeutic, confirming MMF adherence) is essential alongside rejection treatment.910
Antibody-mediated rejection (AMR) is caused by pre-formed or de novo donor-specific antibodies (DSAs) targeting donor human leukocyte antigens (HLAs) on graft endothelium. DSAs activate complement, triggering endothelial injury and microvascular inflammation with the histological signature of peritubular capillary C4d deposition (a complement split product), microvascular injury (peritubular capillaritis, glomerulitis), and in severe cases, thrombotic microangiopathy. AMR carries a significantly worse graft prognosis than TCMR and does not respond to corticosteroids or ATG alone.11 Treatment is directed at removing circulating DSAs and suppressing further antibody production. Plasmapheresis is performed to physically remove DSAs from circulation; typically five to seven sessions are required to achieve meaningful DSA reduction. Intravenous immunoglobulin (IVIG) is administered after each plasmapheresis session to provide replacement immunoglobulins, reduce rebound antibody production, and exert immunomodulatory effects on antibody effector mechanisms. Rituximab (anti-CD20 monoclonal antibody) depletes B cells to reduce de novo DSA production; it is given as a single dose of 375 mg/m². Despite these interventions, AMR frequently leads to chronic allograft injury and progressive graft dysfunction.910
The Banff Classification of Renal Allograft Pathology (updated 2022) provides the international histopathological framework for rejection diagnosis. Key components: tubulitis score (t0–t3), interstitial inflammation score (i0–i3), arteritis score (v0–v3), peritubular capillaritis (ptc0–ptc3), C4d staining (negative/positive), and microvascular injury score. TCMR requires tubulitis and interstitial inflammation without DSA. AMR requires microvascular injury or C4d positivity with DSA. Mixed rejection (both TCMR and AMR features) is treated as AMR-dominant with dual-pathway therapy.
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1–S155.
doi:10.1111/j.1600-6143.2009.02834.xWebster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev. 2005;4:CD003961.
doi:10.1002/14651858.CD003961.pub2Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351(26):2715–2729.
doi:10.1056/NEJMra033540Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation. 1995;60(3):225–232.
doi:10.1097/00007890-199508000-00003Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43(4):329–339.
doi:10.1007/BF02220605Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357(25):2562–2575.
doi:10.1056/NEJMoa067411Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol. 2000;11(9):1735–1743.
doi:10.1681/ASN.V1191735Vincenti F, Lantz M, Birnbaum J, et al. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation. 1997;63(1):33–38.
doi:10.1097/00007890-199701150-00007Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8(4):753–760.
doi:10.1111/j.1600-6143.2008.02159.xNankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med. 2010;363(15):1451–1462.
doi:10.1056/NEJMra0902927Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010;21(8):1398–1406.
doi:10.1681/ASN.2009101065Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 annual data report: kidney. Am J Transplant. 2014;14(Suppl 1):11–44.
doi:10.1111/ajt.12579